Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
On the basis of Xiashi skin surgery clinical experience, this project adopts the multicenter, randomized, double-blind, controlled trial of design type. Objective, normative evaluation of traditional Chinese medicine cool blood latent town effectiveness of therapeutic regimen in the treatment of eczema, security, and control of the relapse of situation, provide high-level evidence-based basis for traditional Chinese medicine treatment of eczema, aims to form suitable for popularization and application of traditional Chinese medicine in the treatment of eczema.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Qinzhuliangxue Keli | Experimental | Qinzhuliangxue Keli(common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets placebo (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.) |
|
| loratadine tablets | Active Comparator | Qinzhuliangxue Keli placebo (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.),Loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.). |
|
| Qinzhuliangxue and loratadine | Active Comparator | Qinzhuliangxue Keli (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Furoic acid loperamide hydrochloride cream | Drug | Apply to lesion area without erosion, drainage, 1 times a day, continuous use 1 week after according to disease reduction or withdrawal, the longest do not exceed 4 weeks. Pure dry area or no skin itching area should not be applied. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from Baseline in the Eczema Area and Severity Index (EASI) score | Baseline and up to week 4 of the follow up phase |
| Measure | Description | Time Frame |
|---|---|---|
| Dermatology life quality index (DLQI) | Baseline and up to week 4 of the follow up phase | |
| Change in Itching degree score | Baseline and up to week 4 of the follow up phase |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Li Bin, director | Contact | 0086-021-65162629 | 18930568129@163.com | |
| Li Fulun, researcher | Contact | 0086-021-65162629 | drlifulun@163.com |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D004485 | Eczema |
| ID | Term |
|---|---|
| D003872 | Dermatitis |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D017443 | Skin Diseases, Eczematous |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Mullite ointment | Drug | Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment |
|
| 3% boric acid solution | Drug | 3% boric acid solution is suitable for the erosion seepage skin, can open intermittent shi fu, 5-10 min each time, 2 times daily or several times. |
|
| Zine oxide | Drug | In wet apply the break to zinc oxide preparation for external use only, when erosion seepage control is disabled in skin lesions. |
|